Shilpa Medicare's Unit IV receives Eurasia GMP approval
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
This approval is a significant achievement in expanding the availability of this critical therapeutic,
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Lidocaine and Prilocaine cream had annual sales of US $22.05 million in the United States (IQVIA MAT October 2024)
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Subscribe To Our Newsletter & Stay Updated